IMGN News Alert Immunogen (IMGN) 7.19 02/14/2015 01:37:30

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 2:37 AM

Immunogen (IMGN) 7.19 $IMGN

Technical Roundup on Biotech Equities - Gilead Sciences, MannKind, ImmunoGen, Dyax, and Pharmacyclics
PR Newswire - Thu Feb 12, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10), IMGN: 7.19 (unch), MNKD: 7.00 (+0.02), DYAX: 15.00 (-0.16)

In Case You Missed It, Researchers May Have Discovered a New Method to Treat Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 07, 6:24AM CST
Macrophages attaching to a cancer cell. Source: Dr. Raowf Guirguis via Wikimedia Commons . Cancer is the second-leading cause of death in the United States, and if projections from the World Health Organization are correct about a nearly 60%...
IMGN: 7.19 (unch), PPHM: 1.28 (+0.03), THLD: 4.03 (+0.21)

ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Business Wire - Wed Feb 04, 10:00AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 7.19 (unch)

Why ImmunoGen, Inc. Shares Rocketed Higher By 25% in January
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 04, 9:05AM CST
IMGN data by YCharts What: Shares of ImmunoGen , a biopharmaceutical company focused on developing antibody-drug conjugates to be used in the fight against cancer, rocketed higher by 25% in January based on data from S&P Capital IQ ...
IMGN: 7.19 (unch)

Critical Alerts For Isis Pharmaceuticals, ImmunoGen, Pixelworks, ManpowerGroup and SouFun Released By InvestorsObserver
PR Newswire - Mon Feb 02, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ISIS, IMGN, PXLW, MAN and SFUN.
PXLW: 5.24 (-0.22), ISIS: 63.86 (-0.43), MAN: 77.51 (+0.77), IMGN: 7.19 (unch), SFUN: 6.74 (-0.01)

Quarterly Results Review & Outlook: Complementary Reports on Costco, Chevron, ImmunoGen, MasterCard, and Intercept
PR Newswire - Mon Feb 02, 6:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Costco (NASDAQ: COST), Chevron (NYSE: CVX), ImmunoGen (NASDAQ: IMGN), MasterCard (NYSE: MA), and Intercept (NASDAQ: ICPT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
IMGN: 7.19 (unch), ICPT: 209.12 (+7.12), COST: 147.10 (-0.66), CVX: 112.78 (+1.92), MA: 87.14 (-0.38)

Update: ImmunoGen Earnings
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 11:44PM CST

IMGN: 7.19 (unch)

ImmunoGen, Inc. Gets Into the Black, Accounting Wise
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 30, 1:15PM CST
ImmunoGen jumped as much as 31% on Friday after announcing earnings results for its second fiscal quarter that ended at the end of the calendar year. The biotech made money this quarter, which might be what investors are excited about, but don't...
IMGN: 7.19 (unch), LLY: 70.56 (+0.03), NVS: 102.20 (-0.17)

ImmunoGen's (IMGN) CEO Daniel Junius on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Jan 30, 1:09PM CST

IMGN: 7.19 (unch)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 11:45AM CST

HIFR: 27.09 (-0.09), HA: 18.72 (-0.31), DECK: 77.08 (+0.61), IMGN: 7.19 (unch), LTRX: 1.74 (+0.02), OHGI: 1.82 (-0.12), GENE: 8.04 (+1.90), BAMM: 2.57 (+0.01), SMLR: 4.54 (+0.20), STRT: 65.10 (+0.29), EGO: 4.94 (+0.10), PFMT: 6.02 (-0.02), GDOT: 15.54 (+0.34), ONCE: 46.25 (+0.07), PSTR: 4.63 (+0.14), ICPT: 209.12 (+7.12), CTP: 6.53 (+0.13), COHR: 64.95 (+0.25), GURE: 1.64 (-0.04)

ImmunoGen guidance unchanged after FQ2 results
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 8:13AM CST

IMGN: 7.19 (unch)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 8:12AM CST

VIP: 5.37 (+0.51), FRO: 2.96 (+0.07), AMZN: 381.83 (+4.66), BIIB: 391.66 (-0.45), PBR.A: 7.13 (+0.48), ALGN: 56.90 (-0.34), SYNA: 78.91 (+0.87), HA: 18.72 (-0.31), INVN: 16.08 (+0.09), IMGN: 7.19 (unch), DECK: 77.08 (+0.61), NBG: 1.61 (+0.18), FXCM: 2.21 (-0.01), VIV: 18.95 (+0.51), SID: 1.76 (+0.06), GENE: 8.04 (+1.90), PBR: 6.98 (+0.44), CIG: 4.29 (+0.10), BBD: 12.90 (+0.30), PFMT: 6.02 (-0.02), SBS: 5.41 (+0.21), QLGC: 14.48 (+0.48), ICPT: 209.12 (+7.12), GURE: 1.64 (-0.04)

ImmunoGen (IMGN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Jan 30, 6:55AM CST

IMGN: 7.19 (unch)

ImmunoGen beats by $0.21, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 5:33AM CST

IMGN: 7.19 (unch)

ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results
Business Wire - Fri Jan 30, 5:30AM CST
--Profit reported for quarter, driven by partner activity; Company reiterates previous financial guidance for fiscal year.
IMGN: 7.19 (unch)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 4:30PM CST

CNX: 33.60 (+0.87), GHM: 22.84 (+0.04), SPG: 193.11 (-1.61), PCAR: 64.22 (+0.98), NS: 61.94 (-0.06), LM: 57.84 (-0.25), BZH: 17.13 (-0.04), NWL: 39.57 (+0.32), MAT: 27.61 (+0.17), MOG.A: 74.61 (+1.47), WY: 35.52 (-0.04), AVY: 53.79 (+0.14), ABBV: 58.05 (+1.00), HMC: 32.87 (+0.14), MA: 87.14 (-0.38), BERY: 34.98 (+0.03), KCG: 12.64 (-0.08), TYC: 43.19 (+0.27), INGR: 82.82 (+0.59), IMGN: 7.19 (unch), MAN: 77.51 (+0.77), IR: 67.69 (+0.06), XRX: 13.77 (+0.20), LLY: 70.56 (+0.03), TSN: 40.70 (-0.09), MO: 54.76 (-0.78), LEA: 108.70 (-0.73), NVO: 43.76 (+0.61), OFG: 17.19 (-0.31), MOSY: 2.10 (+0.02), IDXX: 159.08 (+1.72), SAIA: 45.59 (+0.98), CVX: 112.78 (+1.92), BEN: 53.91 (+0.23), MGIC: 6.40 (+0.03)

Earnings Peek: ImmunoGen Is Undervalued
Clinically Sound Investor - at Seeking Alpha - Mon Jan 26, 8:38AM CST

IMGN: 7.19 (unch)

ImmunoGen reports January 30
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 2:43PM CST

IMGN: 7.19 (unch)

ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2015 Financial Results
Business Wire - Wed Jan 21, 2:40PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January 30, 2015, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2014, the second quarter of its 2015 fiscal year. Management will also provide an update on the Company.
IMGN: 7.19 (unch)

ImmunoGen earns milestone from Novartis
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 11:02AM CST

IMGN: 7.19 (unch), NVS: 102.20 (-0.17)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...